Status:

COMPLETED

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

Lead Sponsor:

Hoffmann-La Roche

Conditions:

Diabetes Mellitus Type 2

Eligibility:

All Genders

30-75 years

Phase:

PHASE2

Brief Summary

This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral GK Activator (2), compared to placebo, in patients with type 2 diabetes mellitus. The anticipated time on stud...

Eligibility Criteria

Inclusion

  • adult patients 30-75 years of age;
  • type 2 diabetes mellitus for \>3 months before screening;
  • treatment-naive, inadequately controlled diabetes despite diet and exercise, or inadequately controlled diabetes in patients on monotherapy or combination therapy (maximum of 2 oral anti-hyperglycemic medications).

Exclusion

  • type 1 diabetes mellitus;
  • women who are pregnant, breast-feeding or not using adequate contraceptive methods.

Key Trial Info

Start Date :

November 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2007

Estimated Enrollment :

267 Patients enrolled

Trial Details

Trial ID

NCT00266240

Start Date

November 1 2005

End Date

May 1 2007

Last Update

November 2 2016

Active Locations (44)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (44 locations)

1

Tucson, Arizona, United States, 85723

2

Pine Bluff, Arkansas, United States, 71603

3

Chula Vista, California, United States, 91911

4

Spring Valley, California, United States, 91978

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus | DecenTrialz